MLICM
GLUE icon

Metropolitan Life Insurance Company (MetLife)’s Monte Rosa Therapeutics GLUE Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,820
Closed -$12.8K – 865
2024
Q1 		$12.8K Hold
1,820
– – ﹤0.01% 2041
2023
Q4 		$10.3K Hold
1,820
– – ﹤0.01% 2173
2023
Q3 		$8.72K Hold
1,820
– – ﹤0.01% 2269
2023
Q2 		$12.5K Hold
1,820
– – ﹤0.01% 2183
2023
Q1 		$14.2K Sell
1,820
-307
-14% -$2.13K ﹤0.01% 2033
2022
Q4 		$16.2K Hold
2,127
– – ﹤0.01% 2107
2022
Q3 		$17.4K Hold
2,127
– – ﹤0.01% 2092
2022
Q2 		$20.6K Hold
2,127
– – ﹤0.01% 2040
2022
Q1 		$29.8K Buy
+2,127
New +$29.5K ﹤0.01% 1888
2021
Q4 		– Sell
-3,598
Closed -$80.2K – 2802
2021
Q3 		$80.2K Buy
+3,598
New +$103K ﹤0.01% 2640

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s GLUE Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Monte Rosa Therapeutics (GLUE) in Q2 2024, closing a stake of 1,820 shares — an estimated $12.8K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in GLUE in Q3 2021 and held it in 10 quarters. The position peaked at $80.2K in Q3 2021. 74 funds tracked by Wall St. Rank hold GLUE as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Monte Rosa Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,820 Monte Rosa Therapeutics shares in Q2 2024, an estimated $12.8K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Monte Rosa Therapeutics in Q3 2021 and held it in 10 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Monte Rosa Therapeutics position peaked at $80.2K in Q3 2021.
  • 74 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.